NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Neumora Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.47−0.00 (-0.80%)

Close on Oct 19, 2026

Market cap: $87.03M
P/E (TTM): –
Dividend yield: –

Neumora Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30
Depreciation & Amortization	0.01	0.01	0.01	0.02	0.02	0.16	0.16	0.16	0.16	0.16	0.17	0.17	0.17	0.16	0.15	–
Stock-Based Compensation	7.18	7.41	7.41	5.98	7.17	9.32	9.90	9.95	13	7.37	6.05	6.45	2.54	2.20	2.79	2.10
Other Non-Cash Items	–	–	–	–	–	–	0.00	–	–	–	-0.07	-0.01	-0.03	-0.02	0.00	–
Change in Accounts Payable	-0.91	1.68	2.83	-0.10	-0.41	-2.26	-2.90	5.03	-0.41	1.16	-1.91	0.31	7.04	-6.01	-3.11	–
Operating Cash Flow	-40	-46	-48	-47	-52	-59	-50	-33	-56	-43	-51	-48	-31	-33	-30	–
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	-0.04	-0.04	0	-0.04	-0.02	–
Sale of Property, Plant & Equipment	0	0.07	0.05	0.09	0.08	0	0	0	–	–	–	–	–	–	–	–
Purchase of Investments	0	0	0	0	-38	-44	-107	0.02	-20	-186	-20	-13	-35	-41	-48	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	–	37	38	–	–	44	40	–
Investing Cash Flow	0	0.07	43	51	30	44	-99	157	21	-150	14	24	24	2.82	-8.03	–
Stock Issued	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Financing Cash Flow	9.29	11	59	-0.14	18	0	16	1.53	2.65	1.85	-0.48	232	0.29	0.10	27	–
Net Change in Cash	-30	-35	53	4.55	-3.55	-15	-134	125	-32	-191	-38	208	-6.65	-30	-12	–
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	-51	-48	-31	-33	-30	–
Income Taxes Paid	0	0.03	0.32	0	0	0	0	0.47	–	–	–	–	–	–	–	–
Interest Paid	1.82	1.85	2.04	0.75	0.44	–	–	0	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -121.2%

Financial strength

Current ratio: 4.50
Debt to equity: 2.54
Debt to assets: 90.2%
Cash to current liabilities: 420.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.95
Dividend yield: –